MENU

Margaret von Mehren, MD

Margaret Von Mehren

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Chief, Division of Sarcoma Medical Oncology 

Physician Director, Clinical Trials Office

Associate Director, Clinical Research

Professor, Department of Hematology/Oncology

TRDG Member, Melanoma and Skin CancerSarcoma and GIST Cancer

NCCN, Adolescent and Young Adult Oncology Panel Member

NCCN, Soft Tissue Sarcoma Panel Member

Treatment Focus

Chemotherapy; tyrosine kinase therapy; immunotherapy

Key Awards

Philadelphia Magazine Top Docs 2018
Medical Oncology

Treatment Philosophy

I first had the opportunity to treat patients with sarcoma during my oncology fellowship training. I really enjoyed the challenge of this area of oncology because of the many types of tumors and their rarity.  When I meet a patient, I work to be certain the pathologic diagnosis is correct and address what we need to do to treat the disease. I collaborate with Fox Chase pathologists, radiologists, surgeons, radiation oncologists and social workers to develop the right treatment plan. We meet as a team weekly at the Sarcoma multi-disciplinary tumor board to review individual patient cases and agree on the best management.

I am also committed to developing new therapies for patients with sarcomas. The strides made in improving cancer care have come from research and clinical trials. I work closely with scientists to better understand gastrointestinal stromal tumors and other sarcomas. I aim to have research studies as a treatment option for my sarcoma patients.

Education and Training

Educational Background

  • Fellow, Hematology/Oncology, Fox Chase Cancer Center and Temple University, Philadelphia, PA
  • Resident, Internal Medicine, New York University Medical Center, NY
  • MD, Albany Medical College, Albany, NY, 1989
  • BS, Biology, Georgetown University, Washington, DC, 1985

Certifications

  • Oncology, Board Certified, 1997, 2007
  • Internal Medicine, Board Certified, 1993

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Adolescent and Young Adult Oncology Panel
    • JNCCN Editorial Board
    • Soft Tissue Sarcoma Panel
  • American Society of Clinical Oncology
  • American Association of Cancer Research
  • Eastern Cooperative Oncology Group
  • Connective Tissue Oncology Society
  • Intergroup Coalition Against Sarcomas, 2003-2007
  • Sarcoma Alliance through Research and Collaboration
  • Medical Advisory and Editorial Board of the of the Liddy Shriver Sarcoma Initiative, 2010-201

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2006-18
  • America’s Top Doctors®, 2015-17
  • Best Doctors in America®, 2013-14
  • Co-Chairman, 2013 GIST NET Global Opinion Leader Summit, Helsinki, FI, 2013
  • Co-Chairman, 2008 GIST Global Opinion Leader Summit, Warsaw, Poland, 2008
  • Clinical Investigator Training Program K-12 Award, Fox Chase Cancer Center, 1996-1998
  • Kenneth B. Olsen Prize, The Lamb Foundation, Inc., 1989
  • Amgen Fellowship Scholarship, American Association of Cancer Research, 1968
Patient Stories

Michelle Palandro

Sarcoma

Michelle Palandro

Sarcoma

Michelle Palandro was a healthy and active 27-year-old woman when she was diagnosed with liposarcoma. After first meeting with an oncologist at a large teaching hospital, Michelle was not convinced that this was the best place for her treatment. She sought a second opinion and was pleased with the compassion and thoroughness of the treatment team at Fox Chase. After undergoing surgery, chemotherapy, and radiation therapy, Michelle is happy to report that she has been cancer free since 2012, and that she gave birth to a healthy baby boy in 2015. "At Fox Chase, every single person I met and every single nurse who took care of me was exceptional."

Robert Smith

Sarcoma

Robert Smith

Sarcoma

I have battled sarcoma several times over the past 20 years. The first time was in 1998 when I was 54 and felt a lump on the side of my torso. Doctors at a community hospital ordered some tests that confirmed the diagnosis of fibrous spindle cell sarcoma. I was given 30 rounds of chemotherapy and continued under the medical supervision of my oncologist for 3 years.

Robert Crossfield

Colorectal Cancer;  Kidney Cancer

Robert Crossfield

Colorectal Cancer;  Kidney Cancer

Robert Crossfield, a 30-year firefighter who was among the team of first responders to the 9/11 disaster where he assisted at Ground Zero, is a survivor of renal and colon cancer and metastatic sarcoma, an aggressive form of cancer. Bob sought treatment at Fox Chase Cancer Center, where he was put under the care of Dr. Margaret von Mehren, Dr. Penny Anderson, Dr. Rosalia Viterbo, and Dr. Jeffrey Farma, as well as reconstructive surgeons Dr. Sameer Patel and Dr. Neal Topham. After undergoing chemotherapy and multiple surgeries, Bob is now cancer free. "I've had aggressive cancers, and multiple cancers, but today I feel healthy again,” Bob said. “This is a battle I'll never give up because I have way too much yet to see and to live for. ...I feel very grateful that we chose Fox Chase to guide us and be with us all the way through this trying time for our family.”

Margaret McCaughey

Sarcoma;  Skin Cancer

Margaret McCaughey

Sarcoma;  Skin Cancer

At 54, Peggy McCaughey is counting her blessings. In addition to her husband, Hugh, and their two daughters, Hannah Rose and Grace Kelly, she feels blessed to be alive. "I am overjoyed to share my experience about Fox Chase Cancer Center,” she says. 

Peggy's journey began with heavy menstrual periods, losing hair and back pain. She shared her concerns with her gynecologist who suggested hormone therapy. “I could not tolerate it,” Peggy recalls.

Maria Bento

GIST (Gastrointestinal Stromal Tumor);  Sarcoma

Maria Bento

GIST (Gastrointestinal Stromal Tumor);  Sarcoma

I have learned many lessons over the years, including the importance of following my instincts and questioning the decisions of others. Those lessons may have saved my life.

Pages

Research Profile

Research Interests

  • Soft tissue and bone sarcomas
  • Gastrointestinal stromal tumors
  • Drug development
  • Clinical trials
Publications

Selected Publications

Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational new drugs, 36(3):476-86, 2018. PubMed

Moten AS, Movva S, von Mehren M, Wu H, Esnaola NF, Reddy SS, Farma JM. Granular cell tumor experience at a comprehensive cancer center. J Surg Res, 226:1-7, 2018. PubMed

von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 36(2):136-43, 2018. ascopubs.org

Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. Oncotargets 2015 Mar 26. [Epub ahead of print]. PubMed

von Mehren M, Bookman M, Meropol N, Weiner L, Sherman E, Li J, Knoblauch R, Parekh T, Cohen R. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 75(5):1047-55, 2015. PubMed

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Gastrointestinal stromal tumors, version 2.2014. Journal of the National Comprehensive Cancer Network, 12(6):853-62, 2014. PubMed

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 12(4):473-83, 2014.

Hensley H, Devarajan K Johnson JR, Piwnica-Worms D, Godwin AK, von Mehren M, Rink L. Evaluating New Therapies in Gastrointestinal Stromal Tumor Using in vivo Molecular Optical Imaging. Cancer Biology and Therapeutics, 15(7):911-8, 2014. PubMed

Demetri G, Reichardt P, Kang Y-K, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381(9863):295-302. 2013. PubMed PMID: 23177515; PubMed Central PMCID: PMC3819942.

Belinsky MG, Rink L, Flieder DB, Jahromi MS, Schiffman JD, Godwin AK, von Mehren M. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes, Chromosomes and Cancer, 52(2):214-24, 2013. PubMed PMID: 23109135; PubMed Central PMCID: PMC3564228.

George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of imatinib and sunitinib: a multicenter phase II trial. Journal of Clinical Oncology, 30(19):2401-7, 2012.

von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. Phase II SWOG-directed Intergroup Trial (S0505) of Sorafenib in Advanced Soft Tissue Sarcomas. Cancer, 118(3):770-6, 2012.

Demetri GD, Wang Y, Wehrle E, Racine, Nikolova Z, Blanke C, Joensuu H, von Mehren M. Imatinib Plasma Levels Correlate With Clinical Benefit in Patients With Unresectable/ Metastatic Gastrointestinal Stromal Tumors (GIST). Journal of Clinical Oncology, 27(19):3141-7, 2009. Epub May 18 2009. PubMed PMID: 18942073; PubMed Central PMCID: PMC2606912.

Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of Neoadjuvant/Adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumors (GIST) – early results of RTOG 0132. Journal of Surgical Oncology, 99(1):42-7, 2009. PubMed

Tarn C, Rink L, Merkel E, Flieder D, Parhak H, Koumbi D, Testa J, Eisenberg B, von Mehren M, Godwin A. Insulin-like Growth Factor 1 Receptor is a Potential Therapeutic Target for Gastrointestinal Stromal Tumors. Proceedings of the National Academy of Sciences, 105(24):8387-92. Epub 2008 Jun 11, 2008. PubMed PMID: 18550829; PubMed Central PMCID: PMC2448846.

von Mehren M, Schilder RJ, Cheng J, Temmer E, Cardoso T, Renshaw G, Bayever E, Zannikos P, Yuan Z, Cohen RB. A Phase I Study of the Safety and Pharmacokinetics of Trabectedin in Combination With Pegylated Liposomal Doxorubicin in Patients With Advanced Malignancies. Annals of Oncology, 19(10):1802-9, 2008. PubMed PMID: 18497430; PubMed Central PMCID: PMC2598415.

Blanke CD*, Demetri GD*, von Mehren M*, Heinrich M, Eisenburg B, Fletcher J, Coreless C, Fletcher CD, Heinz D, Wehre E, Nikolova Z, Joensuu H*. Long Term Results from a Randomized Phase II Trial of Standard versus Higher Dose Imatinib Mesylate for Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. Journal of Clinical Oncology, 16: 626-632, 2008.*Authors contributed equally to the article. PubMed

Additional Publications

MyNCBI

Ratings

85 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.8
  • 4.9
  • 4.9
  • 5.0
  • 4.9

12 PATIENT COMMENTS

  • 5.0
    August 28, 2018
    Our family loves Dr. Vonmehren!!
  • 5.0
    July 09, 2018
    Doctor has been outstanding over this many years of treatment.
  • 5.0
    June 28, 2018
    She is the best research oncologist for my cancer GIST that I could ever hope to have helping me.
  • 5.0
    May 09, 2018
    I was not fully aware of all the questions I should have asked, but what I did ask was answered well.
  • 5.0
    April 30, 2018
    I truly believe I'm alive because of Dr. Vonmehren's care.
  • 5.0
    April 27, 2018
    A++
  • 5.0
    April 26, 2018
    Dr Von Mehren was outstanding. I left the consultation feeling much better about my issues
  • 5.0
    April 11, 2018
    I've been seeing Dr. Vonmehren for the past 18 years. We have a bond.
  • 5.0
    April 03, 2018
    Dr. Vonmehren gave me a second opinion on options following a sarcoma surgery. I value her opinion, her knowledge, intelligence, forthright and professionalism. Outstanding!
  • 5.0
    April 02, 2018
    Dr. Vonmehren always takes the time to answer my questions & concerns. Once personally called me about test results!
  • 5.0
    March 15, 2018
    She's the perfect combination of professional knowledge & compassion.
  • 5.0
    February 19, 2018
    Dr. Vonmehren is the best.
LOAD MORE

Connect with Fox Chase